tiprankstipranks
Advertisement
Advertisement

DAWN Stock Latest News

Oracle, Nike upgraded: Wall Street’s top analyst calls
The FlyOracle, Nike upgraded: Wall Street’s top analyst calls
16d ago
HAS
HOG
Day One downgraded to Neutral from Overweight at JPMorgan
PremiumThe Fly
Day One downgraded to Neutral from Overweight at JPMorgan
17d ago
DAWN
Qualcomm downgraded, Rivian upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Qualcomm downgraded, Rivian upgraded: Wall Street’s top analyst calls
17d ago
LTH
NVO
Day One Biopharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Day One Biopharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
17d ago
DAWN
Day One Biopharma Earnings Call Highlights Ojemda Surge
PremiumCompany Announcements
Day One Biopharma Earnings Call Highlights Ojemda Surge
20d ago
DAWN
Hold Rating on Day One Biopharmaceuticals as Servier’s $2.5 Billion Takeout Caps Upside at $21.50 Target
PremiumRatingsHold Rating on Day One Biopharmaceuticals as Servier’s $2.5 Billion Takeout Caps Upside at $21.50 Target
21d ago
DAWN
Midday Fly By: Rising oil prices, falling employment sink stocks
Premium
The Fly
Midday Fly By: Rising oil prices, falling employment sink stocks
21d ago
BA
BX
Day One Biopharmaceuticals downgraded to Hold from Buy at TD Cowen
Premium
The Fly
Day One Biopharmaceuticals downgraded to Hold from Buy at TD Cowen
21d ago
DAWN
Day One Biopharmaceuticals downgraded to Neutral from Overweight at Piper Sandler
PremiumThe Fly
Day One Biopharmaceuticals downgraded to Neutral from Overweight at Piper Sandler
21d ago
DAWN
Day One Biopharmaceuticals downgraded to Hold from Buy at Needham
PremiumThe Fly
Day One Biopharmaceuticals downgraded to Hold from Buy at Needham
21d ago
DAWN
Day One Biopharmaceuticals downgraded to Neutral from Outperform at Wedbush
PremiumThe Fly
Day One Biopharmaceuticals downgraded to Neutral from Outperform at Wedbush
21d ago
DAWN
Day One Biopharmaceuticals downgraded to Hold from Buy at JonesResearch
PremiumThe Fly
Day One Biopharmaceuticals downgraded to Hold from Buy at JonesResearch
21d ago
DAWN
Servier to Acquire Day One Biopharmaceuticals in Merger
PremiumCompany AnnouncementsServier to Acquire Day One Biopharmaceuticals in Merger
21d ago
8K
DAWN
Day One Biopharmaceuticals trading resumes
Premium
The Fly
Day One Biopharmaceuticals trading resumes
21d ago
DAWN
Servier to acquire Day One for $21.50 per share in cash
Premium
The Fly
Servier to acquire Day One for $21.50 per share in cash
21d ago
DAWN
Day One Biopharmaceuticals trading halted, news pending
PremiumThe Fly
Day One Biopharmaceuticals trading halted, news pending
21d ago
DAWN
Day One jumps 26% to $12.59 after Betaville mention
PremiumThe Fly
Day One jumps 26% to $12.59 after Betaville mention
23d ago
DAWN
Day One Biopharmaceuticals up 11% after rumor highlighted in Betaville blog
PremiumThe Fly
Day One Biopharmaceuticals up 11% after rumor highlighted in Betaville blog
23d ago
DAWN
Day One Biopharmaceuticals: Ojemda Uptake, Strong 2026 Guidance, and Underappreciated Emi‑Le Catalyst Support Buy Rating
PremiumRatings
Day One Biopharmaceuticals: Ojemda Uptake, Strong 2026 Guidance, and Underappreciated Emi‑Le Catalyst Support Buy Rating
24d ago
DAWN
Day One Highlights OJEMDA’s EMA Progress, Updates Strategy
PremiumCompany AnnouncementsDay One Highlights OJEMDA’s EMA Progress, Updates Strategy
25d ago
8K
DAWN
Day One Biopharmaceuticals price target raised to $30 from $29 at Wedbush
Premium
The Fly
Day One Biopharmaceuticals price target raised to $30 from $29 at Wedbush
1M ago
DAWN
Day One Biopharmaceuticals: Durable OJEMDA Launch, De‑Risked Revenue Outlook, and Clinical Catalysts Underpin Buy Rating and $17 Price Target
Premium
Ratings
Day One Biopharmaceuticals: Durable OJEMDA Launch, De‑Risked Revenue Outlook, and Clinical Catalysts Underpin Buy Rating and $17 Price Target
1M ago
DAWN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >